Pfizer Suspends Patient Enrollment In Late-stage Cancer Drug Trial

Published: 12-Oct-2009

Pfizer has notified clinical trial investigators and regulatory agencies about the action

Pfizer has suspended patient enrollment in its late-stage lung cancer study of figitumumab, also known as CP-751871, due to serious adverse events, including deaths – reported Trading Markets. The experimental drug was being tested in combination with carboplatin and paclitaxel in patients with nonsmall-cell lung cancer.

Reportedly, in the study, some patients with non-small cell lung cancer received figitumumab along with carboplatin and paclitaxel, while some others received only carboplatin and paclitaxel. The objective of the study was to assess the safety and efficacy of figitumumab as a potential initial treatment.

Reportedly, after finding more adverse events in patients who received figitumumab, independent safety monitors overseeing the study recommended that the study be halted. Pfizer has notified clinical trial investigators and regulatory agencies about the action. The company plans to work with the safety monitoring committee to analyze the data before issuing further guidance. Pfizer has added that currently enrolled patients may continue their treatment after consulting their doctors, reported the website.

Tell your friend about this article